Wilmington Savings Fund Society FSB Buys New Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Wilmington Savings Fund Society FSB purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 950 shares of the company’s stock, valued at approximately $149,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Raymond James & Associates raised its holdings in TransMedics Group by 152.4% during the second quarter. Raymond James & Associates now owns 23,444 shares of the company’s stock worth $3,531,000 after purchasing an additional 14,156 shares in the last quarter. EFG Asset Management North America Corp. raised its stake in shares of TransMedics Group by 12.4% in the 2nd quarter. EFG Asset Management North America Corp. now owns 21,196 shares of the company’s stock worth $3,191,000 after buying an additional 2,343 shares in the last quarter. SlateStone Wealth LLC bought a new stake in shares of TransMedics Group in the 2nd quarter worth $856,000. HB Wealth Management LLC acquired a new stake in shares of TransMedics Group in the second quarter valued at $318,000. Finally, F M Investments LLC bought a new position in TransMedics Group during the second quarter valued at about $10,957,000. 99.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,417 shares of company stock worth $2,240,738 in the last quarter. 7.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on TMDX. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Down 0.6 %

NASDAQ:TMDX opened at $60.53 on Friday. TransMedics Group, Inc. has a 1-year low of $60.17 and a 1-year high of $177.37. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of 64.39 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business’s fifty day moving average price is $89.89 and its 200 day moving average price is $129.32.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.12) EPS. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.